Abstract
Traditionally the brain has been viewed as being an immune-privileged organ. However, endogenous stimuli such as the presence of misfolded or aggregated proteins, as well as systemic inflammatory events may lead to the activation of microglial cells, the brain´s innate immune system, and, subsequently, to neuroinflammation. Alzheimer's disease, the leading cause of dementia, is characterized by amyloid beta deposition and tau hyperphosphorylation. Neuroinflammation in Alzheimer's disease has been identified as major contributor to disease pathogenesis. Once activated, microglia release several pro and anti-inflammatory mediators of which several affect the function and structure of the brain. Modulation of this microglial activation in Alzheimer's disease might open new therapeutic avenues.
Keywords: Alzheimer's, amyloid-β, cytokines, neuroinflammation, neurodegeneration, microglia.
Current Alzheimer Research
Title:Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly
Volume: 13 Issue: 4
Author(s): Dario Tejera and Michael T. Heneka
Affiliation:
- Clinical Neuroscience Unit, Department of Neurology, University of Bonn. Sigmund Freud Strasse 25, 53127, Bonn, Germany,Germany
Keywords: Alzheimer's, amyloid-β, cytokines, neuroinflammation, neurodegeneration, microglia.
Abstract: Traditionally the brain has been viewed as being an immune-privileged organ. However, endogenous stimuli such as the presence of misfolded or aggregated proteins, as well as systemic inflammatory events may lead to the activation of microglial cells, the brain´s innate immune system, and, subsequently, to neuroinflammation. Alzheimer's disease, the leading cause of dementia, is characterized by amyloid beta deposition and tau hyperphosphorylation. Neuroinflammation in Alzheimer's disease has been identified as major contributor to disease pathogenesis. Once activated, microglia release several pro and anti-inflammatory mediators of which several affect the function and structure of the brain. Modulation of this microglial activation in Alzheimer's disease might open new therapeutic avenues.
Export Options
About this article
Cite this article as:
Tejera Dario and Heneka T. Michael, Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly, Current Alzheimer Research 2016; 13(4) . https://dx.doi.org/10.2174/1567205013666151116125012
DOI https://dx.doi.org/10.2174/1567205013666151116125012 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Polyethylenimine-based Formulations for Delivery of Oligonucleotides
Current Medicinal Chemistry De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Hsp90: A Novel Target for Cancer Therapy
Current Topics in Medicinal Chemistry 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets
Current Pharmaceutical Design Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells
Current Medicinal Chemistry Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs (Discontinued) The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science 5-HT5 Receptors
Current Drug Targets - CNS & Neurological Disorders Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry G-Protein Coupled Receptor Resensitization - Appreciating the Balancing Act of Receptor Function
Current Molecular Pharmacology The Safety of the Temozolomide in Patients with Malignant Glioma
Current Drug Safety A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry